Clinical Trials
Neoadjuvant niraparib shows activity in HRD-positive ovarian cancer in phase 2 trial
Liu et alThe Lancet Oncology

In the multicentre, single-arm, phase 2 NANT trial, neoadjuvant niraparib monotherapy demonstrated clinical anti-tumour activity in patients presenting with unresectable, homologous recombination deficiency (HRD)-positive high-grade serous ovarian cancer.
Treatment with niraparib enabled complete (R0) surgical resection in selected patients with advanced disease who were initially assessed as unsuitable for primary debulking surgery.
Currently, neoadjuvant PARP inhibitor monotherapy remains investigational. Randomised clinical trials comparing this approach directly against standard-of-care neoadjuvant platinum-taxane chemotherapy regimens are required to establish its clinical efficacy and role in standard practice.
Key Takeaways
- Neoadjuvant niraparib monotherapy demonstrated anti-tumour activity and enabled R0 resection in selected patients with unresectable, HRD-positive high-grade serous ovarian cancer initially deemed unsuitable for primary debulking surgery.
- Neoadjuvant niraparib monotherapy remains an investigational strategy requiring randomised trial validation against standard neoadjuvant platinum-taxane chemotherapy.
Read the original sourceThe Lancet Oncology
